Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(4), P. 519 - 519

Published: April 18, 2024

Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether early reduction or at week 12 treatment could be maintained later stages. retrospective involved 227 73 moderate-to-severe AD treated 15 30 mg daily, respectively. The eczema area severity index (EASI) scores, peak numerical rating scale (PP-NRS), investigator’s global assessment (IGA) were analyzed. At 12, divided into achievers non-achievers EASI 75, 90, 100, absolute ≤ 2, IGA0/1, PP-NRS4, PP-NRS 1. Achievement rates each endpoint assessed time points (weeks 24, 36, 48) both groups. Week largely their achievements until 48, regardless dosage (15 mg). saw an increasing achievement rate 75 48. initial persisted 48 treatment, suggesting potential benefits requiring prolonged despite not achieving 12.

Language: Английский

---

Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis

Dermatitis, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Upadacitinib, a Janus kinase 1 inhibitor, is an effective medicine for moderate-to-severe atopic dermatitis (AD). Identifying long-term responders to upadacitinib crucial optimal treatment strategies in real-world clinical practice. To identify predictive factors high 15 mg or 30 mg, defined as achievers of investigator's global assessment (IGA) 0/1 with ≥2-point improvement from baseline IGA at week 48.

Language: Английский

---

Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 54 - 54

Published: Jan. 1, 2025

Background and Objectives: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating JAK-STAT signalling pathway. While these proven effective, they also pose challenges due to associated increase in serum lipid levels relative potential cardiovascular risks. This perspective work aims discuss implications alterations proposing management strategies for patients with disorders under JAKi treatments. Materials Methods: manuscript reviews existing recent literature on metabolic effects JAKi, particularly focusing their impact profiles treated diseases. Results: JAK are consistently an both LDL HDL shortly after initiation, which tend stabilise over time. Despite changes, there is no clear evidence linking increased risk major adverse events (MACE), indicating a complex interaction between metabolism signalling. Conclusions: Although may induce changes patients, raising concerns, especially ones risks, currently link MACE this population. Monitoring levels, alongside lifestyle modifications possible statin use, can manage without need stopping treatment.

Language: Английский

---

New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review

Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 631 - 631

Published: March 29, 2025

Prurigo nodularis (PN) is a chronic dermatological condition characterized by intensely pruritic nodules resulting from repeated scratching. Its pathogenesis involves neuroimmune dysregulation, inflammatory cytokines, and neural proliferation. Conventional treatments often provide limited relief, necessitating novel therapeutic approaches. This narrative review explores emerging biologics small molecules for PN treatment, assessing their mechanisms, efficacy, safety. A comprehensive literature search was conducted using PubMed, Google Scholar, Web of Science relevant studies up to February 2025. Additionally, ongoing clinical trials were identified through ClinicalTrials.gov. The terms included “prurigo nodularis”, “biologic treatments”, “monoclonal antibodies”, “small molecules”, “JAK inhibitors”. Among new treatment options, dupilumab, an IL-4 receptor antagonist, nemolizumab, IL-31 inhibitor, demonstrated significant efficacy in reducing pruritus lesion severity patients. Other promising monoclonal antibodies include vixarelimab (OSMRβ inhibitor) barzolvolimab (KIT inhibitor). Small such as JAK inhibitors (upadacitinib, povorcitinib) also show potential modulating pathways. Clinical highlight safety, long-term benefits. Emerging represent transformative approach management, offering targeted therapies that address underlying immunological neurological mechanisms. Ongoing research are crucial optimizing strategies improving patient outcomes.

Language: Английский

---

Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel

Dermatology and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

---

Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2953 - 2953

Published: April 24, 2025

Background: Atopic dermatitis (AD) is a chronic pruritic inflammatory disease affecting children and adults. Upadacitinib abrocitinib are selective Janus kinase 1 inhibitors approved for the treatment of moderate-to-severe AD. Although their efficacy safety described in phase 3 clinical trials, real-world data limited. Objectives: We aimed to evaluate effectiveness upadacitinib real-life adult population with AD throughout an extended observation period. Methods: This retrospective observational study was conducted by analyzing from electronic records IRCCS Humanitas Research Hospital January 2023 December 2024. Patients were administered either (15 or 30 mg) (100 200 mg). Effectiveness evaluated using clinician-reported scores (Investigator Global Assessment [IGA] Eczema Area Severity Index [EASI]) patient-reported outcomes (peak pruritus numerical rating scale [PP-NRS]) at weeks 8, 16, 32 52. Statistical significance set probability value (p-value) < 0.05. Adverse events also collected. Results: In total, 129 patients included study, 84 them reached 52 weeks. At week 52, EASI 75, 90, 100 responses 88.9%, 70.8%, 54.2% upadacitinib, 100%, 91.7%, 75% abrocitinib. An IGA score equal 0 achieved 84.7% treated 100% those receiving A four-point reduction baseline PP-NRS reported 86.1% 83.3% after one year follow-up. Conclusions: Our showed comparable even higher terms compared phase-3 no new concerns, supporting

Language: Английский

---

Current and emerging drugs for the treatment of pruritus: an update of the literature

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(6), P. 655 - 672

Published: April 12, 2024

Pruritus, particularly in its chronic form, often imposes significant suffering and reductions patients' quality of life. The pathophysiology itch is varied depending on disease context, creating opportunities for unique drug development multimodal therapy.

Language: Английский

---

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: July 4, 2024

Language: Английский

---

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)

Journal of Dermatological Treatment, Journal Year: 2024, Volume and Issue: 35(1)

Published: Oct. 10, 2024

Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted 16-week multicenter retrospective study to assess short-term effectiveness and safety abrocitinib in patients with AD.

Language: Английский

---